0000899243-19-001157.txt : 20190114
0000899243-19-001157.hdr.sgml : 20190114
20190114210914
ACCESSION NUMBER: 0000899243-19-001157
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181112
FILED AS OF DATE: 20190114
DATE AS OF CHANGE: 20190114
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Nussbaum Robert L
CENTRAL INDEX KEY: 0001640322
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36847
FILM NUMBER: 19526083
MAIL ADDRESS:
STREET 1: 458 BRANNAN STREET
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94107
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Invitae Corp
CENTRAL INDEX KEY: 0001501134
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071]
IRS NUMBER: 271701898
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1400 16TH STREET
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94103
BUSINESS PHONE: (415) 374-7782
MAIL ADDRESS:
STREET 1: 1400 16TH STREET
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94103
FORMER COMPANY:
FORMER CONFORMED NAME: InVitae Corp
DATE OF NAME CHANGE: 20121105
FORMER COMPANY:
FORMER CONFORMED NAME: Locus Development Inc
DATE OF NAME CHANGE: 20100910
4/A
1
doc4a.xml
FORM 4/A SUBMISSION
X0306
4/A
2018-11-12
2018-11-14
0
0001501134
Invitae Corp
NVTA
0001640322
Nussbaum Robert L
C/O INVITAE CORPORATION
1400 16TH STREET
SAN FRANCISCO
CA
94103
0
1
0
0
Chief Medical Officer
Common Stock
2018-11-12
4
S
0
8244
13.0036
D
171191
D
Common Stock
2018-11-12
4
S
0
2200
13.5282
D
168991
D
These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on August 10, 2018.
The transaction code was incorrectly reported and transactions not within a one dollar price range were inadvertently aggregated on the reporting person's original Form 4.
Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
Represents weighted average sale price. Actual sale prices ranged from $12.40 to $13.38.
Includes an aggregate of 164,235 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
Represents weighted average sale price. Actual sale prices ranged from $13.40 to $13.66.
/s/ Patty Dumond, Attorney-in-Fact
2019-01-14